01
Architect the foundation
Build programs that answer the right clinical and regulatory questions by design.
Evidence strategy for programs without precedent
We help first-in-class therapies assemble the evidence needed to succeed.
- Clinical + regulatoryPrograms, protocols, endpoints, and agency strategy
- Value + accessRWE, HTA, pricing, and economic evidence
- Evidence executionLifecycle delivery, executive support, and applied AI
One connected evidence system
Capabilities
Four connected pillars bring ten specialist capabilities into one responsive evidence strategy—from early program architecture through launch, access, and lifecycle execution.
02
Translate for access
Connect clinical evidence to the value questions payers and HTAs will ask.
03
Drive lifecycle value
Plan and execute evidence that remains useful before and after launch.
04
Enable evidence execution
Turn strategy into governed workflows, decisions, and durable operating capability.
Selected public engagements
Case studies
Representative programs showing how we work across uncertainty, evidence generation, and high-stakes decisions.
Showing all 9 case studies
01Regulatory strategy
De Novo · first-in-class PDT
Pathway design, three-trial evidence synthesis, and an investor-ready narrative.
Read case study 02Value translationTrial evidence → payer value
A unified value story connecting clinical outcomes with payer-facing evidence.
Read case study 03Pre-launchRare disease · MA and RWE
Disease burden, KOL priorities, and pre-launch medical affairs evidence.
Read case study 04Post-launchRare disease · post-launch RWE
Specialty channels, claims, and evidence for medical and payer strategy.
Read case study 05Executive decision supportBD · asset and clinical diligence
An integrated asset view supporting executive go / no-go decisions.
Read case study 06Clinical developmentCombination therapy · evidence lead
Cross-functional evidence strategy for a partnered clinical-stage asset.
Read case study 07Pricing and accessImmunology · pricing and access
HTA-linked pricing, rebate modeling, and competitive share scenarios.
Read case study 08Program designGene therapy · first-in-human
Global FIH design, endpoints, and age-descending regulatory strategy.
Read case study 09Lifecycle expansionGene therapy · pediatric expansion
Natural history and burden-of-disease evidence supporting expansion.
Read case studyStart with the decision you need to make
Let’s assemble the right evidence.
Bring us a first-in-class development, regulatory, access, or portfolio decision. We typically respond within two business days.
info@lotorlab.com